Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPC Biotech To Resubmit Orplatna With Overall Survival Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Company announces it will withdraw the NDA for satraplatin for prostate cancer based on outcome of advisory committee meeting.
Advertisement

Related Content

Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
GPC Biotech Plans Restructuring To Cut Costs Following SPARC Failure
GPC Biotech Plans Restructuring To Cut Costs Following SPARC Failure
GPC Retrenches While Awaiting Satraplatin Data
GPC Retrenches While Awaiting Satraplatin Data
ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative
ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative

Topics

Advertisement
UsernamePublicRestriction

Register

PS066400

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel